Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study

These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib.

Authors

Institutions

Publication Details

Journal
Oncology
Published
2024-10-11
DOI
https://doi.org/10.1159/000541018
Citations
5
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
1.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study

Francesco Giuseppe Foschi, Silvia Foti, Silvia Camera, Jaekyung Cheon et al.
5 citations
Oncology
Hepatocellular Carcinoma Treatment and Prognosis
1.85
article

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study

Francesco Giuseppe Foschi, Silvia Foti, Silvia Camera, Jaekyung Cheon, Hideko Ohama, Norio Itokawa, Joji Tani, Ho Yeong Lim, José Presa, Kazuhito Kawata, Margherita Rimini, Luigi Mascia, Kazuya Kariyama, Fabian Finkelmeier, Naoya Sakamoto, Goki Suda, Hironori Ochi, Giuseppe Cabibbo, Hidenori Toyoda, Francesca Bergamo, Kazuhiro Nouso, Takeshi Hatanaka, Naoshi Nishida, Christoph Steup, Fabio Piscaglia, Masatoshi Kudo, Mara Persano, Mario Scartozzi, Yoichi Hiasa, Caterina Vivaldi, Shigeo Shimose, Atsushi Hiraoka, Stefano Cascinu, Takashi Kumada, Francesco Vitiello, Tomomi Okubo, Takuya Nagano, Ei Itobayashi, Vera Himmelsbach, Takuya Sho, Masaki Kaibori, Mariangela Bruccoleri, Gianluca Masi, Masashi Hirooka, Hiroko Iijima, Chikara Ogawa, Hisashi Kosaka, Federico Rossari, Kazuto Tajiri, Takashi Nishimura, Hong Jae Chon, Caterina Soldà, Toshifumi Tada, Atsushi Naganuma, Margarida Montes, Akemi Tsutsui, Toru Ishikawa, Masanori Atsukawa, Tomoko Aoki, Fujimasa Tada, Hideki Iwamoto, Massimo Alberto Iavarone, Asahiro Morishita, Andrea Casadei‐Gardini, Koichi Takaguchi, Michitaka Imai, Satoru Kakizaki, Changhoon Yoo, Elisabeth Amadeo, Yohei Koizumi, Takashi Niizeki, Satoshi Yasuda, Noritomo Shimada, Shinichiro Nakamura, Kunihiko Tsuji
article en
5 citations

Abstract

These results suggest that, in patients with HCC progressed to first-line atezolizumab plus bevacizumab, lenvatinib second-line therapy is associated to an improved survival compared to sorafenib.

OncologyVol. 103(6)
Kurume University (JP), University of Pisa (IT), Goethe University Frankfurt (DE), Ulsan College (KR), Kansai Medical University (JP), Vita-Salute San Raffaele University (IT), University of Cagliari (IT), Kagawa University (JP), Hokkaido University (JP), Samsung Medical Center (KR), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Hamamatsu University School of Medicine (JP), University of Ulsan (KR), Ospedale Maggiore (IT), Takamatsu Red Cross Hospital (JP), Saiseikai Niigata Daini Hospital (JP), Istituto Oncologico Veneto (IT), National Hospital Organization Takasaki Medical Center (JP), Matsuyama Red Cross Hospital (JP), Okayama Prefecture (JP), Azienda USL di Bologna (IT), Ospedale per gli Infermi (IT), Ogaki Municipal Hospital (JP), University Hospital Frankfurt (DE), Gunma Saiseikai Maebashi Hospital (JP), Himeji Red Cross Hospital (JP), CHA University Bundang Medical Center (KR), Teine Keijinkai Hospital (JP), Direção Geral do Território (PT), The San Raffaele Telethon Institute for Gene Therapy (IT), Asahi General Hospital (JP), Toyama University Hospital (JP), Ehime Prefectural Central Hospital (JP), CHA University (KR), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Kagawa Prefectural Central Hospital (JP), Otemae Hospital (JP), Azienda Ospedaliera Universitaria Pisana (IT), Azienda Ospedaliera G. Brotzu (IT), Ehime University (JP), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Gifu Kyoritsu University (JP), Nippon Medical School (JP), Hyogo University (JP), Sungkyunkwan University (KR), University of Palermo (IT), Kindai University (JP)
Partnerships for the goals
Openalex Percentile: Top 14%
Hepatocellular Carcinoma Treatment and Prognosis
1.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.